InsidersTradesSigma
Bio-Gate AG Stock: price and directors' dealings · Germany · BaFin
Track the Bio-Gate AG stock price and the full management transaction log of the company, a publicly traded company based in Germany. Shares are quoted on DE DE, under the oversight of BaFin. Operating in the Healthcare & Pharma sector, Bio-Gate AG has logged 3 reports. Market capitalisation: €6.8m. The latest transaction was reported on 22 August 2025 (Other). Among the most active insiders: Konradt, Thomas. All data is accessible without an account.
3
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
15Σ signal
Fundamental score
Ranked 23,913 of 26,132 companies
20.3
score / 100
Value10
Quality30
FCF yld-22%
Earn yld-18%
EV/EBITDA·
ROE-72%
Gross mgn58%
Net mgn-16%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 August 2025
Declarations3 total
11 shares@ €10,000.00100.0% of flowDebt instrumentBAFIN:40004794-7bc197c98f87
1 shares@ €50,000.0050.0% of flowDebt instrumentBAFIN:40004794
1 shares@ €50,000.0050.0% of flowDebt instrumentBAFIN:40004794-dea18c771e93
3 of 3 declarations
About Bio-Gate AG
Bio-Gate AG is a German healthcare technology company listed on Xetra/Frankfurt (DAX/MDAX/SDAX), operating as a niche specialist at the intersection of human health, animal health, and surface hygiene. Headquartered in Germany, with operating sites in Nuremberg and Bremen, the company develops and commercializes antimicrobial and antiviral solutions designed to improve safety in hygiene-sensitive environments. Its business model is based on the monetization of proprietary technologies applied to materials, products, and surfaces, rather than on the sale of conventional pharmaceuticals. Founded in the early 2000s, Bio-Gate has built its expertise around two core technology platforms. The first is HyProtect™, an ultrathin plasma coating designed to reduce bacterial colonization on medical implants, particularly in orthopaedics. The second is MicroSilver BG™, an antimicrobial and antiviral additive that can be integrated into a wide range of materials and formulations. This technological base allows the group to address several end markets: medical devices, dermatological care and wound management, veterinary products, and industrial/consumer hygiene applications. From a competitive standpoint, Bio-Gate is differentiated less by scale than by specialization, intellectual property, and its ability to industrialize niche solutions with added value. The company collaborates with universities and research institutes and operates an independent microbiological testing subsidiary, QualityLabs BT GmbH, which strengthens the scientific credibility of its development work. In parallel, Bio-Gate is expanding veterinary products through VetInnovations, with increasing commercial reach in Europe and North America. Recent disclosures point to gradual operational improvement. In 2025, the company reported an expanded North American presence in veterinary care, while clinical data supported the commercialization of medical CBD-based care products. In December 2024, Bio-Gate announced a key step toward serial production of HyProtect™-coated orthopaedic implants, with a clinical study underway for CE approval. For fiscal 2025, the company reported in April 2026 revenue of EUR 7.4 million and a narrower net loss, indicating that operating leverage is developing, albeit from a still modest base. For investors, Bio-Gate remains a German micro/small-cap innovation story exposed to attractive end markets, but still in the scaling phase.
